PDCD1 and uveal melanoma: Here, we report a single-center retrospective analysis comparing clinical outcomes of ipilimumab plus nivolumab versus anti-PD-1 monotherapy in patients with metastatic uveal melanoma treated at the National Institute of Oncology, Budapest.